Posted: 12/28/2024 03:25 am
Biomerica, Inc. (NASDAQ: BMRA), a company operating within the in vitro and in vivo diagnostic substances industry, has shown notable compensation trends over the past years. The compensation packages for key personnel have varied significantly from 2020 to 2024, reflecting both the company's strategic decisions and broader industry trends.
In 2020, Zackary Irani, Chairman and CEO, received a total compensation of $330,481, primarily through a combination of salary ($136,606) and option awards ($193,875)[^5]. The same year, Steve Sloan, Chief Financial Officer & Treasurer, was compensated with $0, indicating that he either joined the company with a non-standard compensation package or was not active in a paid capacity during that period[^4]. This changed in 2021 when Sloan's compensation reached $553,566, largely due to a substantial option award of $386,900, the largest among his compensatory elements[^3].
Allen Barbieri, who holds multiple roles as Director, Executive Vice Chairman, and Secretary, has had varied compensation across different years. In 2022, Barbieri received a total of $355,954, which remarkably included a $10,000,000 bonus—an anomalous figure that starkly contrasts the usual compensation elements, suggesting a significant one-time financial event or milestone achieved by the company[^2]. His 2024 compensation was notably lower at $243,983, absent any bonus but featuring option awards totaling $119,400[^1].
These fluctuations within the compensation regime align with Biomerica's broader financial performance challenges. Currently, the company's stock is trading at $0.3154, reflecting a decline of 2.95% from the previous day[^6]. Over the past year, the stock has ranged between $0.24 and $1.35, indicative of considerable volatility[^6]. This share price behavior, coupled with a negative earnings per share (EPS) of -$0.37, underscores ongoing financial difficulties[^6]. The company’s market capitalization stands at approximately $5.3 million, with trading volumes significantly below the 50-day and 200-day average, suggestive of diminished investor interest[^6].
Overall, while Biomerica's executive compensation has demonstrated significant variability, particularly with large bonuses and option awards shared among top executives, the company faces substantive hurdles in achieving stability in its market performance and stock price. This dual reality presents a complex landscape for stakeholders evaluating Biomerica's strategic and financial future.
---
[^1]: "SEC 2024 Compensation Data for Allen Barbieri," U.S. Securities and Exchange Commission, https://www.sec.gov/Archives/edgar/data/73290/000149315224038820/0001493152-24-038820-index.htm.
[^2]: "SEC 2022 Compensation Data for Allen Barbieri," U.S. Securities and Exchange Commission, https://www.sec.gov/Archives/edgar/data/73290/000149315223034447/0001493152-23-034447-index.htm.
[^3]: "SEC 2021 Compensation Data for Steve Sloan," U.S. Securities and Exchange Commission, https://www.sec.gov/Archives/edgar/data/73290/000151316222000119/0001513162-22-000119-index.htm.
[^4]: "SEC 2020 Compensation Data for Steve Sloan," U.S. Securities and Exchange Commission, https://www.sec.gov/Archives/edgar/data/73290/000151316221000114/0001513162-21-000114-index.htm.
[^5]: "SEC 2020 Compensation Data for Zackary Irani," U.S. Securities and Exchange Commission, https://www.sec.gov/Archives/edgar/data/73290/000151316220000207/0001513162-20-000207-index.htm.
[^6]: "Biomerica, Inc. Current Stock Snapshot," NASDAQ, accessed from Market Data.
